Compare Adobe Systems Inc (ADBE) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Inovio Pharmaceuticals Inc — how do they compare? Adobe Systems Inc trades at $258.41 (market cap $104.82B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Adobe Systems Inc is far larger — about 1334.4× Inovio Pharmaceuticals Inc's market cap, and Adobe Systems Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | INO | |
|---|---|---|
Market Cap | $104.82B | $78.55M |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $2.87 |
52-Week Low | $193.41 | $0.66 |
Enterprise Value | $106.26B | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $256.30, down 6.1% on the day amid broader tech sector weakness. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $5.96 versus $5.82 expected. Technical indicators show a bullish moving average trend but neutral oscillators, with key support at $252. Revenue grew to $23.77B in 2025 with impressive 28.69% net margins.
Adobe presents a compelling value opportunity trading below analyst consensus targets despite AI competition concerns. The company's robust cash flow generation and market leadership in creative software support long-term growth, though investor sentiment remains cautious due to CEO transition and AI disruption risks. Wall Street maintains a buy-heavy rating with $248.86 average price target.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
